Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedSite update from v3.4.1 to v3.4.2 involves minor UI/bug fixes and no substantive changes to the study record or its critical information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check23 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous v3.4.0. This is a minor site metadata update and does not alter the study details.SummaryDifference0.1%

- Check30 days agoChange DetectedShow glossary added and ORR/DCR definitions updated to RECIST 1.1 criteria with duration notes (e.g., 'Throughout study duration, up to approx 80 months'). Additionally, metadata updates were added, including 'Last Update Submitted that Met QC Criteria', 'Revision: v3.4.0', and 'No FEAR Act Data'.SummaryDifference0.8%

- Check45 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded a dedicated Locations section with New York as a site; the old New York Locations header was removed and the page updated to revision v3.3.3.SummaryDifference0.2%

- Check95 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.